Loading...

Pro Medicus

ASX:PME
Snowflake Description

Flawless balance sheet with outstanding track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PME
ASX
A$2B
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions worldwide. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Pro Medicus has significant price volatility in the past 3 months.
PME Share Price and Events
7 Day Returns
-1.9%
ASX:PME
-0.8%
AU Healthcare Services
0.7%
AU Market
1 Year Returns
122.3%
ASX:PME
59.1%
AU Healthcare Services
4.7%
AU Market
PME Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pro Medicus (PME) -1.9% -3.1% 25% 122.3% 328.8% 1921.4%
AU Healthcare Services -0.8% 5.2% 22.7% 59.1% 63.2% 460.9%
AU Market 0.7% 1.1% 6.5% 4.7% 17.5% 4.9%
1 Year Return vs Industry and Market
  • PME outperformed the Healthcare Services industry which returned 59.1% over the past year.
  • PME outperformed the Market in Australia which returned 4.7% over the past year.
Price Volatility
PME
Industry
5yr Volatility vs Market

Value

 Is Pro Medicus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Pro Medicus to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Pro Medicus.

ASX:PME Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:PME
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.21
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.214 (1 + (1- 30%) (0%))
1.143
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.143 * 5.96%)
9.13%

Discounted Cash Flow Calculation for ASX:PME using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Pro Medicus is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:PME DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 9.13%)
2019 16.40 Analyst x3 15.03
2020 20.83 Analyst x4 17.49
2021 26.73 Analyst x4 20.56
2022 31.56 Est @ 18.08% 22.25
2023 35.77 Est @ 13.35% 23.11
2024 39.36 Est @ 10.04% 23.30
2025 42.40 Est @ 7.72% 23.00
2026 44.98 Est @ 6.1% 22.36
2027 47.21 Est @ 4.96% 21.51
2028 49.18 Est @ 4.17% 20.53
Present value of next 10 years cash flows A$209.16
ASX:PME DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$49.18 × (1 + 2.31%) ÷ (9.13% – 2.31%)
A$738.30
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$738.30 ÷ (1 + 9.13%)10
A$308.25
ASX:PME Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$209.16 + A$308.25
A$517.41
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$517.41 / 103.62
A$4.99
ASX:PME Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$4.99
Current discount Discount to share price of A$16.98
= -1 x (A$16.98 - A$4.99) / A$4.99
-240%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Pro Medicus is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pro Medicus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pro Medicus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:PME PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.18
ASX:PME Share Price ** ASX (2019-04-18) in AUD A$16.98
Global Healthcare Services Industry PE Ratio Median Figure of 37 Publicly-Listed Healthcare Services Companies 38.05x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pro Medicus.

ASX:PME PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PME Share Price ÷ EPS (both in AUD)

= 16.98 ÷ 0.18

94.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pro Medicus is overvalued based on earnings compared to the Global Healthcare Services industry average.
  • Pro Medicus is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Pro Medicus's expected growth come at a high price?
Raw Data
ASX:PME PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 94.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
20.7%per year
Global Healthcare Services Industry PEG Ratio Median Figure of 26 Publicly-Listed Healthcare Services Companies 2.45x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

ASX:PME PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 94.28x ÷ 20.7%

4.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pro Medicus is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Pro Medicus's assets?
Raw Data
ASX:PME PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.40
ASX:PME Share Price * ASX (2019-04-18) in AUD A$16.98
Australia Healthcare Services Industry PB Ratio Median Figure of 15 Publicly-Listed Healthcare Services Companies 3.09x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:PME PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PME Share Price ÷ Book Value per Share (both in AUD)

= 16.98 ÷ 0.40

42.75x

* Primary Listing of Pro Medicus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pro Medicus is overvalued based on assets compared to the AU Healthcare Services industry average.
X
Value checks
We assess Pro Medicus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Pro Medicus has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pro Medicus expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pro Medicus expected to grow at an attractive rate?
  • Pro Medicus's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Pro Medicus's earnings growth is expected to exceed the Australia market average.
  • Pro Medicus's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:PME Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:PME Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 20.7%
ASX:PME Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 14.1%
Global Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
Australia Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 27.7%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:PME Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:PME Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 64 35 28 4
2020-06-30 54 29 22 4
2019-06-30 48 24 18 4
ASX:PME Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 45 14 19
2018-09-30 41 14 16
2018-06-30 36 14 13
2018-03-31 34 14 9
2017-12-31 32 15 8
2017-09-30 32 15 9
2017-06-30 32 15 9
2017-03-31 30 13 9
2016-12-31 28 12 8
2016-09-30 28 11 7
2016-06-30 28 11 6
2016-03-31 25 9 5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pro Medicus's earnings are expected to grow significantly at over 20% yearly.
  • Pro Medicus's revenue is expected to grow by 14.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:PME Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Pro Medicus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PME Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.27 0.31 0.22 4.00
2020-06-30 0.21 0.24 0.17 4.00
2019-06-30 0.17 0.19 0.16 4.00
ASX:PME Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.18
2018-09-30 0.15
2018-06-30 0.12
2018-03-31 0.09
2017-12-31 0.08
2017-09-30 0.08
2017-06-30 0.09
2017-03-31 0.09
2016-12-31 0.08
2016-09-30 0.07
2016-06-30 0.06
2016-03-31 0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Pro Medicus is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Pro Medicus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Global market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pro Medicus has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pro Medicus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pro Medicus's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pro Medicus has delivered over 20% year on year earnings growth in the past 5 years.
  • Pro Medicus's 1-year earnings growth exceeds its 5-year average (141.4% vs 41.9%)
  • Pro Medicus's earnings growth has exceeded the Global Healthcare Services industry average in the past year (141.4% vs 16.2%).
Earnings and Revenue History
Pro Medicus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pro Medicus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PME Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 45.39 18.63 13.55
2018-09-30 40.68 15.69 13.22
2018-06-30 35.96 12.74 12.89
2018-03-31 33.79 9.29 12.69
2017-12-31 32.30 7.72 12.41
2017-09-30 31.95 8.52 12.22
2017-06-30 31.60 9.32 12.02
2017-03-31 30.02 8.77 12.14
2016-12-31 28.45 8.22 12.26
2016-09-30 27.98 7.30 12.55
2016-06-30 27.52 6.37 12.84
2016-03-31 25.34 5.46 12.60
2015-12-31 23.17 4.55 12.36
2015-09-30 20.33 3.88 11.33
2015-06-30 17.49 3.22 10.29
2015-03-31 17.20 3.07 9.62
2014-12-31 16.92 2.92 8.95
2014-09-30 15.59 2.21 8.43
2014-06-30 14.27 1.51 7.91
2013-12-31 11.31 0.57 8.20
2013-09-30 11.23 -1.45 8.27
2013-06-30 11.15 -3.48 8.34
2012-12-31 11.17 -3.61 8.41
2012-09-30 11.24 -1.43 8.02
2012-06-30 11.31 0.76 7.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Pro Medicus made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Pro Medicus used its assets more efficiently than the Global Healthcare Services industry average last year based on Return on Assets.
  • Pro Medicus has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Pro Medicus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pro Medicus has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pro Medicus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pro Medicus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pro Medicus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pro Medicus's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pro Medicus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Pro Medicus has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pro Medicus Company Filings, last reported 3 months ago.

ASX:PME Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 41.13 0.00 24.74
2018-09-30 41.13 0.00 24.74
2018-06-30 45.66 0.00 25.24
2018-03-31 45.66 0.00 25.24
2017-12-31 39.37 0.00 22.80
2017-09-30 39.37 0.00 22.80
2017-06-30 34.83 0.00 22.78
2017-03-31 34.83 0.00 22.78
2016-12-31 31.25 0.00 20.28
2016-09-30 31.25 0.00 20.28
2016-06-30 27.39 0.00 17.11
2016-03-31 27.39 0.00 17.11
2015-12-31 25.15 0.00 16.19
2015-09-30 25.15 0.00 16.19
2015-06-30 21.94 0.00 12.94
2015-03-31 21.94 0.00 12.94
2014-12-31 21.44 0.00 14.65
2014-09-30 21.44 0.00 14.65
2014-06-30 20.71 0.00 15.26
2013-12-31 20.79 0.00 17.84
2013-09-30 20.79 0.00 17.84
2013-06-30 20.96 0.00 18.02
2012-12-31 20.99 0.00 18.36
2012-09-30 20.99 0.00 18.36
2012-06-30 16.00 0.00 5.19
  • Pro Medicus has no debt.
  • Pro Medicus has not taken on any debt in the past 5 years.
  • Pro Medicus has no debt, it does not need to be covered by operating cash flow.
  • Pro Medicus has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Pro Medicus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pro Medicus has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pro Medicus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.41%
Current annual income from Pro Medicus dividends. Estimated to be 0.65% next year.
If you bought A$2,000 of Pro Medicus shares you are expected to receive A$8 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Pro Medicus's pays a lower dividend yield than the bottom 25% of dividend payers in Australia (2.5%).
  • Pro Medicus's dividend is below the markets top 25% of dividend payers in Australia (5.81%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:PME Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 15 Stocks 1.3%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:PME Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.13 4.00
2020-06-30 0.10 4.00
2019-06-30 0.10 4.00
ASX:PME Past Annualized Dividends Data
Date (Data in A$) Dividend per share (annual) Avg. Yield (%)
2019-02-20 0.070 0.446
2018-08-15 0.070 0.647
2018-02-15 0.050 0.631
2017-08-17 0.050 0.748
2017-02-16 0.030 0.583
2016-08-19 0.030 0.583
2016-02-18 0.030 0.715
2015-08-21 0.020 0.702
2015-02-20 0.020 1.062
2014-08-22 0.020 1.870
2014-02-26 0.020 2.363
2013-08-29 0.020 3.287
2013-02-21 0.020 4.161
2012-08-24 0.020 4.606
2012-02-24 0.010 3.365
2011-08-30 0.000 0.000
2010-08-26 0.020 5.526
2010-02-25 0.000 0.000
2009-08-31 0.035 4.478
2009-04-20 0.048 6.568

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pro Medicus is not paying a notable dividend for Australia, therefore no need to check if the payments are stable.
  • Pro Medicus is not paying a notable dividend for Australia, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Pro Medicus's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Pro Medicus's dividends as it is not paying a notable one for Australia.
Future Payout to shareholders
  • No need to calculate the sustainability of Pro Medicus's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Pro Medicus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pro Medicus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pro Medicus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pro Medicus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sam Hupert
COMPENSATION A$518,339
TENURE AS CEO 8.5 years
CEO Bio

Dr. Sam Aaron Hupert, M.B.B.S. has been the Chief Executive Officer and Managing Director at Pro Medicus Limited (alternate name: PRO Medicus Ltd.) since October 2010. Dr. Hupert serves as Chief Executive Officer of Visage Imaging, Inc. Dr. Hupert served as Managing Director of PRO Medicus Ltd. until October 1, 2007. Dr. Hupert co-founded Pro Medicus Limited in 1983. Realising the significant potential for computers in medicine he left general practice in late 1984 to devote himself full time to managing Pro Medicus Ltd. He served as the Chief Executive Officer at PRO Medicus Ltd. since 1983 until October 1, 2007. He serves as Deputy Chairman and Executive Director of Visage Imaging, Inc. He has been Deputy Chairman at PRO Medicus Ltd. since October 1, 2007 and also serves as its Executive Director October 2007. He was a Director at PRO Medicus since 1983 until October 2007. He is a Monash University Medical School graduate (MBBS) who commenced General Practice in 1980.

CEO Compensation
  • Sam's compensation has been consistent with company performance over the past year.
  • Sam's remuneration is lower than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Pro Medicus management team in years:

8.3
Average Tenure
  • The average tenure for the Pro Medicus management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Sam Hupert

TITLE
Co-Founder
COMPENSATION
A$518K
TENURE
8.5 yrs

Anthony Hall

TITLE
Co-Founder
COMPENSATION
A$385K
TENURE
36.3 yrs

Malte Westerhoff

TITLE
Global Chief Technology Officer
COMPENSATION
A$763K

Brad Levin

TITLE
GM of North America & Global Head of Marketing
COMPENSATION
A$455K

Danny Tauber

TITLE
General Manager of Australia
COMPENSATION
A$391K
TENURE
8.3 yrs

Sean Lambright

TITLE
Global Head of Sales - Visage Imaging Inc
COMPENSATION
A$572K
TENURE
3.8 yrs

Clayton Hatch

TITLE
CFO & Company Secretary
TENURE
6.8 yrs

Teresa Gschwind

TITLE
Global Head of Customer Service of Visage Imaging Inc.
Board of Directors Tenure

Average tenure of the Pro Medicus board of directors in years:

8.7
Average Tenure
  • The tenure for the Pro Medicus board of directors is about average.
Board of Directors

Peter Kempen

TITLE
Chairman of the Board
COMPENSATION
A$100K
AGE
69
TENURE
8.7 yrs

Sam Hupert

TITLE
Co-Founder
COMPENSATION
A$518K
TENURE
11.5 yrs

Anthony Hall

TITLE
Co-Founder
COMPENSATION
A$385K
TENURE
36.3 yrs

Tony Glenning

TITLE
Non-Executive Director
COMPENSATION
A$100K
TENURE
2.9 yrs

Leigh Farrell

TITLE
Non- Executive Director
COMPENSATION
A$75K
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Pro Medicus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pro Medicus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Want To Invest In Pro Medicus Limited (ASX:PME)? Here's How It Performed Lately

In this commentary, I will examine Pro Medicus Limited's (ASX:PME) latest earnings update (30 June 2018) and compare these figures against its performance over the past couple of years, as well as how the rest of the healthcare services industry performed. … PME's trailing twelve-month earnings (from 30 June 2018) of AU$13m has … However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 48%, indicating the rate at which PME is growing has slowed down.

Simply Wall St -

What Do You Get For Owning Pro Medicus Limited (ASX:PME)?

and looking to gauge the potential return on investment in Pro Medicus Limited (ASX:PME). … Your return is tied to PME’s ability to do this because the amount earned is used to invest in opportunities to grow the business or payout dividends, which are the two sources of return on investment. … Thus, to understand how your money can grow by investing in Pro Medicus, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE)

Simply Wall St -

Should You Be Impressed By Pro Medicus Limited's (ASX:PME) ROE?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every A$1 worth of equity in the company, it was able to earn A$0.28. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

When Should You Buy Pro Medicus Limited (ASX:PME)?

led the ASX gainers with a relatively large price hike in the past couple of weeks. … So, could the stock still be trading at a low price relative to its actual value. … Let’s take a look at Pro Medicus’s outlook and value based on the most recent financial data to see if the opportunity still exists

Simply Wall St -

Pro Medicus Limited (ASX:PME): Assessing Capital Returns

You need to pay attention to this because your return on investment is linked to dividends and internal investments to improve the business, which can only occur if the company is expected to produce adequate earnings with the capital that has been provided. … Therefore, looking at how efficiently Pro Medicus is able to use capital to create earnings will help us understand your potential return. … Investors use many different metrics but the analysis below focuses on return on capital employed (ROCE).

Simply Wall St -

Should Pro Medicus Limited's (ASX:PME) Recent Earnings Worry You?

For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. … Were PME's earnings stronger than its past performances and the industry. … PME's trailing twelve-month earnings (from 31 December 2017) of AU$9.59m has

Simply Wall St -

What You Must Know About Pro Medicus Limited's (ASX:PME) Financial Strength

Pro Medicus Limited (ASX:PME), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is PME right in choosing financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

What Makes Pro Medicus Limited (ASX:PME) An Attractive Investment?

Attractive stocks have exceptional fundamentals. … In the case of Pro Medicus Limited (ASX:PME), there's … financially-healthy

Simply Wall St -

Pro Medicus Limited (ASX:PME): Are Forecast Margins sustainable?

Pro Medicus Limited's (ASX:PME) … encouraging earnings sentiment … drives analysts to forecast

Simply Wall St -

Does The Hype Around Pro Medicus Limited's (ASX:PME) Growth Justify Its June Share Price?

Pro Medicus's extremely high growth potential in the near future is attracting investors. … The stock is trading at a lofty price-to-earnings (PE) ratio of 81.49x, telling us that Pro Medicus is overvalued based on current earnings compared to the healthcare services industry average of 39.58x , and overvalued compared to the AU market average ratio of 17x. … But, since Pro Medicus is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio.

Simply Wall St -

Company Info

Description

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions worldwide. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.

Details
Name: Pro Medicus Limited
PME
Exchange: ASX
Founded: 1983
A$1,759,408,475
103,616,518
Website: http://www.promed.com.au
Address: Pro Medicus Limited
450 Swan Street,
Richmond,
Victoria, 3121,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PME Ordinary Shares Australian Securities Exchange AU AUD 10. Oct 2000
OTCPK PMCU.F Ordinary Shares Pink Sheets LLC US USD 10. Oct 2000
DB PMC Ordinary Shares Deutsche Boerse AG DE EUR 10. Oct 2000
CHIA PME Ordinary Shares Chi-X Australia AU AUD 10. Oct 2000
Number of employees
Current staff
Staff numbers
0
Pro Medicus employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 10:31
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/10
Last earnings filing: 2019/02/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.